In Vitro Evaluation of a Specific Radiochemical Compound Based on 99mTc-labeled DARPinG3 for Radionuclide Imaging of Tumors Overexpressing Her-2/neu; AIP Conference Proceedings; Vol. 1882 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17)

Dettagli Bibliografici
Parent link:AIP Conference Proceedings
Vol. 1882 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17).— 2017.— [020007, 4 p.]
Altri autori: Bragina O. D. Olga Dmitrievna, Larkina M. S. Mariya Sergeevna, Stasyuk (Stasiuk) E. S. Elena Sergeyevna, Chernov V. I. Vladimir Ivanovich, Zelchan (Zeltchan) R. V. Roman Vladimirovich, Medvedeva А. А. Anna Aleksandrovna, Sinilkin I. G. Ivan Gennadjevich, Yusubov M. S. Mekhman Suleiman-Ogly (Suleimanovich), Skuridin V. S. Viktor Sergeyevich, Deev S. M. Sergey Mikhaylovich, Buldakov M.
Riassunto:Title screen
It is still necessary to search for new informative diagnostic methods to detect malignant tumors with overexpression of Her-2/neu, which are characterized by the aggressive course of the disease, rapid rate of tumor growth and low rates of relapse-free and overall survival. In recent years, the radioisotope techniques for detection of specific tumor targets have been developing actively. Purpose: to develop a chemically stable radiochemical compound for the targeted imaging of cells overexpressing Her-2/neu. Material and methods: The study was performed using 2 cell lines .The human breast adenocarcinoma HER2-overexpressing cell line BT-474 was chosen to detect specific binding. As a control, HER2-negative human breast adenocarcinoma MCF-7 was used. The human breast adenocarcinoma BT-474 and MCF-7 cell lines were seeded in chamber-slides at the density of 35,000 cells/ml in trypsin-EDTA (PanEco) medium and grown overnight at 37°C. After that both cell lines were washed with Phosphate buffered saline (PBS) and distributed into test tubes to 1 ml (5 millions cells in each). After adding 100 [mu]l (70 MBq) studied complex of 99mTc-DPAH-DARPinG3 was incubated for 40 min at +4°C.
Washing was performed three times with buffer PBS and 5% Bovine Serum Albumin (BSA). The characteristics of the binding specificity of the test set with the HER-2/neu receptor were determined by direct radiometric and planar scintigraphy. Nonparametric Mann-Whitney test was used to assess the differences in the quantitative characteristics between groups. Results: The output of the labeled complex was more than 91%, with a radiochemical purity of more than 94%. When carrying out a visual scintigraphic assessment much greater intensity accumulation of radiotracer was observed in the studied cell culture surface receptor overexpressing Her-2/neu. The results of direct radiometric also showed higher accumulation of the radiopharmaceutical in the adenocarcinoma cell line BT-474 human breast cancer overexpressing Her-2/neu compared to the control group. Conclusion: The preclinical studies demonstrated a high in vitro stability of the study compound, as well as its accumulation in the cell group overexpressing Her-2/neu.
Режим доступа: по договору с организацией-держателем ресурса
Lingua:inglese
Pubblicazione: 2017
Soggetti:
Accesso online:https://doi.org/10.1063/1.5001586
http://earchive.tpu.ru/handle/11683/46894
Natura: Elettronico Capitolo di libro
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=657720

MARC

LEADER 00000naa2a2200000 4500
001 657720
005 20251204155318.0
035 |a (RuTPU)RU\TPU\network\24433 
035 |a RU\TPU\network\24431 
090 |a 657720 
100 |a 20180313a2017 k y0engy50 ba 
101 0 |a eng 
135 |a drgn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a In Vitro Evaluation of a Specific Radiochemical Compound Based on 99mTc-labeled DARPinG3 for Radionuclide Imaging of Tumors Overexpressing Her-2/neu  |f O. D. Bragina, M. S. Larkina, E. S. Stasyuk (Stasiuk) [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 12 tit.] 
330 |a It is still necessary to search for new informative diagnostic methods to detect malignant tumors with overexpression of Her-2/neu, which are characterized by the aggressive course of the disease, rapid rate of tumor growth and low rates of relapse-free and overall survival. In recent years, the radioisotope techniques for detection of specific tumor targets have been developing actively. Purpose: to develop a chemically stable radiochemical compound for the targeted imaging of cells overexpressing Her-2/neu. Material and methods: The study was performed using 2 cell lines .The human breast adenocarcinoma HER2-overexpressing cell line BT-474 was chosen to detect specific binding. As a control, HER2-negative human breast adenocarcinoma MCF-7 was used. The human breast adenocarcinoma BT-474 and MCF-7 cell lines were seeded in chamber-slides at the density of 35,000 cells/ml in trypsin-EDTA (PanEco) medium and grown overnight at 37°C. After that both cell lines were washed with Phosphate buffered saline (PBS) and distributed into test tubes to 1 ml (5 millions cells in each). After adding 100 [mu]l (70 MBq) studied complex of 99mTc-DPAH-DARPinG3 was incubated for 40 min at +4°C. 
330 |a Washing was performed three times with buffer PBS and 5% Bovine Serum Albumin (BSA). The characteristics of the binding specificity of the test set with the HER-2/neu receptor were determined by direct radiometric and planar scintigraphy. Nonparametric Mann-Whitney test was used to assess the differences in the quantitative characteristics between groups. Results: The output of the labeled complex was more than 91%, with a radiochemical purity of more than 94%. When carrying out a visual scintigraphic assessment much greater intensity accumulation of radiotracer was observed in the studied cell culture surface receptor overexpressing Her-2/neu. The results of direct radiometric also showed higher accumulation of the radiopharmaceutical in the adenocarcinoma cell line BT-474 human breast cancer overexpressing Her-2/neu compared to the control group. Conclusion: The preclinical studies demonstrated a high in vitro stability of the study compound, as well as its accumulation in the cell group overexpressing Her-2/neu. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 0 |0 (RuTPU)RU\TPU\network\4816  |t AIP Conference Proceedings 
463 0 |0 (RuTPU)RU\TPU\network\24427  |t Vol. 1882 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17)  |o Proceedings of the International conference, 23–26 May 2017, Tomsk, Russia  |f National Research Tomsk Polytechnic University (TPU) ; eds. E. Y. Gutmanas, O. B. Naimark, Yu. P. Sharkeev  |v [020007, 4 p.]  |d 2017 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a опухоли 
610 1 |a диагностические методы 
610 1 |a злокачественные опухоли 
610 1 |a радиохимические соединения 
610 1 |a выживаемость 
610 1 |a визуализация 
610 1 |a радиометрические исследования 
610 1 |a радиофармацевтические препараты 
701 1 |a Bragina  |b O. D.  |c specialist in the field of medical technology  |c Senior Researcher of the Tomsk Polytechnic University, Doctor of Medical Sciences  |f 1986-  |g Olga Dmitrievna  |y Tomsk  |3 (RuTPU)RU\TPU\pers\35943  |9 19084 
701 1 |a Larkina  |b M. S.  |g Mariya Sergeevna  |f 1984-  |c pharmacist  |c Professor; Senior Researcher of the Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences  |3 (RuTPU)RU\TPU\pers\46781  |9 22417 
701 1 |a Stasyuk (Stasiuk)  |b E. S.  |c Specialist in the field of nuclear power engineering  |c Researcher of Tomsk Polytechnic University, Candidate of technical sciences  |f 1978-  |g Elena Sergeyevna  |3 (RuTPU)RU\TPU\pers\32656  |9 16555 
701 1 |a Chernov  |b V. I.  |c specialist in the field of medical technology  |c lead engineer of Tomsk Polytechnic University, doctor of medical sciences  |f 1962-  |g Vladimir Ivanovich  |3 (RuTPU)RU\TPU\pers\34191  |9 17725 
701 1 |a Zelchan (Zeltchan)  |b R. V.  |c specialist in the field of medical technology  |c Researcher of the Tomsk Polytechnic University, Candidate of Medical Sciences  |f 1984-  |g Roman Vladimirovich  |3 (RuTPU)RU\TPU\pers\34194  |9 17728 
701 1 |a Medvedeva  |b А. А.  |g Anna Aleksandrovna  |f 1975-  |c specialist in the field of medical technology  |c research fellow of Tomsk Polytechnic University, Doctor of Medical Sciences  |3 (RuTPU)RU\TPU\pers\37376  |9 20294 
701 1 |a Sinilkin  |b I. G.  |c specialist in the field of medical technology  |c laboratory, Tomsk Polytechnic University, candidate of medical science  |f 1972-  |g Ivan Gennadjevich  |3 (RuTPU)RU\TPU\pers\34189  |9 17723 
701 1 |a Yusubov  |b M. S.  |c chemist  |c Professor of Tomsk Polytechnic University, Doctor of chemical sciences  |f 1961-  |g Mekhman Suleiman-Ogly (Suleimanovich)  |3 (RuTPU)RU\TPU\pers\31833  |9 15928 
701 1 |a Skuridin  |b V. S.  |c Physicist, Specialist in the field of nuclear power engineering  |c Professor of Tomsk Polytechnic University, Doctor of technical sciences  |f 1946-  |g Viktor Sergeyevich  |3 (RuTPU)RU\TPU\pers\32655  |9 16554 
701 1 |a Deev  |b S. M.  |c biologist  |c Leading Researcher, Tomsk Polytechnic University, Doctor of Biological Sciences  |f 1951-  |g Sergey Mikhaylovich  |3 (RuTPU)RU\TPU\pers\39299  |9 20959 
701 1 |a Buldakov  |b M. 
801 2 |a RU  |b 63413507  |c 20210302  |g RCR 
856 4 |u https://doi.org/10.1063/1.5001586  |z https://doi.org/10.1063/1.5001586 
856 4 |u http://earchive.tpu.ru/handle/11683/46894  |z http://earchive.tpu.ru/handle/11683/46894 
942 |c CF